Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI and Blinatumomab in Haploidentical HCT for Hematologic Malignancies
NCT07052370Phase 1Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD45RA depleted donor lymphocyte infusion and blinatumomab in hematologic malignancy, sponsored by St. Jude Children's Research Hospital. Primary endpoint: Number of participants experiencing grade 3-4 GVHD and/or transplant related mortality (TRM) at 100 days. Started Sep 2025; status: recruiting.
02
Drugs
CD45RA depleted donor lymphocyte infusionblinatumomab
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT07052370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052370.